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ance Research Database between 1 January 2000 and 31 December 2008. All
patients received at least two prescriptions for statins and used continuously for at
least 6months during the study periodwere included as the study cohort. Of these,
cases were identified as subjects with the first diagnosis of breast cancer and
matched to randomly selected controls. Hazard ratios were used to estimate the
risk associated with exposure to statin use and breast cancer by Cox proportional
hazards model adjusted for co-morbidities, menopause, diabetes, use of other lip-
id-lowering agents, hormone replacement therapy, cardiovascular drugs and non-
steroidal anti-inflammatory drugs. RESULTS: We identified 99 breast patients
among 17166 statin users from 2001 to 2008. The mean follow-up period was 3.5
years. We found a significant risk of breast cancer among statin users in age-
adjusted (hazard ratio(HR)1.63, 95% confidence interval: (1.301,2.033) , p 0.0001)
and multivariate analysis(HR:1.42, 95% CI: (1.103,1.825),p0.0065). The risk of
breast cancer did not differ significantly in stratified analysis of covariates. How-
ever, a suggestive increased risk of breast cancer among statin users of pre-meno-
pausal, co-administered with cardiovascular drugs and NSAIDs was found.
CONCLUSIONS: This study is likely to support an association between statin use
and breast cancer risk in the population of Chinese.
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OBJECTIVES: Emerging evidence suggests that diabetes may increase the risk of
cancers. Available evidence on prostate cancer, however, is conflicting. We there-
fore examined the association between type 2 diabetes and risk of prostate cancer
by conducting a detailed meta-analysis of prospective cohort studies published
regarding this subject. METHODS: PubMed database, CINAHL, EMBASE, and bibli-
ographies of retrieved articles were searched for prospective cohort studies (pub-
lished between 1970 and 2011) investigating the relationship between type 2 dia-
betes and prostate cancer. Pooled risk ratio (RR) was calculated using random-
effects model (DerSimonian and Laird method). Heterogeniety was calculated
using Cochrane’s Q test. To find out heterogeniety we performed subgroup analy-
sis. Sensitivity analysis and cumulative meta-analysis were also done. RESULTS:
Twenty-nine cohort studies involving 5.1 million participants and 92,331 prostate
cancer cases detected a significant inverse association between type 2 diabetes and
risk of prostate cancer (RR 0.87 (95% CI 0.80-0.94)). Sensitivity analysis done by
excluding one outlier further strengthened our negative association (RR 0.82, 95%
CI 0.76-0.84). This association was not substantially modified by Prostate-specific
antigen testing, number of covariates adjustment and adjustment for BMI or obe-
sity. Cumulative meta-analysis showed a change in trend of reporting risk of pros-
tate cancer from positive to negative in type 2 diabetes patients between 1970 and
2011. No evidence of publication bias was observed. CONCLUSIONS: Our meta-
analysis provides strongest evidence supporting that type 2 diabetes is signifi-
cantly inversely associated with risk of developing prostate cancer.
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OBJECTIVES: Studies examining the association between type 2 diabetes and the
risk of breast cancer in women have small sample sizes and inconclusive results.
This study systematically reviews the risk of breast cancer in diabetic women and
compares the risk of breast cancer in Caucasian and Asian women with type 2
diabetes. METHODS: Data for this meta-analysis were extracted from MEDLINE
and EMBASE databases from years 1975 to 2010. Initial search of risk of breast
cancer in women with type 2 diabetes yielded 33 studies. Out of the 33 studies
found in the search, 22 studies met the inclusion criteria with 16 and 6 studies
involving Caucasian and Asian women with a risk of breast cancer, respectively.
RESULTS: The 22 studies analyzed using STATA®SE version10 involved a total of
77,204women (47,083 Caucasians and 30,121Asians).Meta analysis results showed
that overall, women with type 2 diabetes had a 30.5% significantly higher risk of
breast cancer (RR, 1.305; 95% CI, 1.30-1.31). Compared to Western women, Asian
women with type 2 diabetes had 51.9% significantly higher risk of developing
breast cancer (RR, 1.519; 95% CI, 1.508-1.530). CONCLUSIONS: The study shows that
womenwith type 2 diabeteswere likely to be, as a group, at increased risk for breast
cancer, with a relatively higher risk among Asian women. The efficacy of enhance-
ments in glycemic control management, improving insulin sensitivity with exer-
cise and diet control and screening for breast cancer particularly in Asian women
with type 2 diabetes warrants further study.
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OBJECTIVES: A universally accepted staging system for hepatocellular carcinoma
(HCC) has not been adopted. The goal of this work is to assess survival and treat-
ment patterns of HCC patients stratified by the National Comprehensive Cancer
Network (NCCN) staging-guided treatment categories. METHODS: An HCC retro-
spective research registry was developed from linking records in the University of
Utah Enterprise Data Warehouse, the Utah Population Database, and the Hunts-
manCancer Institute Tumor Registry. Patient recordswere included if age 18, at
least one HCC ICD-9 code, documented hepatocellular carcinoma or cholangiocar-
cinoma in the tumor registry, and the presence of informative staging data around
the time of diagnosis. Patients were stratified by the NCCN groupings by chart
review around the time of diagnosis as either: potentially resectable or operable
(RESECT), transplantable (TRANSP), unresectable (UNRESCT), inoperable due to
performance status (INOPER), or having metastatic (METAST) disease. Treatment
patterns and survival were evaluated. RESULTS: A total of 221 patients (161 males,
72.9%) with HCC were identified. At the time of diagnosis 12.7% subjects (n28)
were considered RESCT; 14.9% (n33) TRANSP; 34.8% (n77) UNRESCT; 18.1%
(n40) INOPER, and 17% (n38) METAST. Staging informationwas not available for
5 subjects (2.3%). Kaplan-Meier analysis demonstrated statistically significant dif-
ferences in all groups except between RESCT and TRANSP patients and between
UNRESCT and INOPER patients. Themedian days of survival were 594, 562, 247, 167
and 44 for RESCT, TRANSP, UNRESCT, INOPER, and METAST patients respectively.
RESECT patients most frequently received early resection (61%) and TRANSP pa-
tients had the highest utilization of liver transplant (33%). Utilization of any treat-
ment was low in the METAST (31.6%) and INOPER (60%) groups. CONCLUSIONS:
Treatment patterns were distinct across the NCCN groupings and aligned with
NCCN treatment guidelines. Overall the NCCN groupings predict overall survival.
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OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for around a third of all leukaemia diagnoses. Treatment, which can be
given with supportive and/or curative intent, is expensive with costly medical
interventions and lengthy hospitalization (often due to complications). Despite
this, little is knownabout its lifetime economic burdenwith few studies attempting
to cost the entire treatment pathway. This investigation aimed to address these
issues by estimating the phase-specific and lifetime pathway costs of a UK cohort
of AML patients. METHODS: The Haematological Malignancy Research Network
(HMRN, www.hmrrn.org), is a population-based study, that has registered newly
diagnosed patients with haematological malignancies in two UK cancer networks.
All adults (18) newly diagnosed with AML from September 2004 to August 2007
were included in the current study (n382). The bottom-up method was used to
cost each treatment, and lifetime costs were calculated by linking the treatment
costs to the treatment pathway. Treatment pathways and medical resource con-
sumption were derived from HMRN and National Hospital Episode Statistics (HES).
Unit costs were determined from various sources, including the British National
Formulary and NHS reference costs. RESULTS: The average lifetime treatment cost
and survival life-years per patient were £40,324(554-247,432) and 5.3 (0.7-68.3)
months, respectively. This cost was largely determined by first-line treatment and
the number of relapses. The major cost-driver throughout all treatment phases
was hospitalization, followed by the costs of drugs and treatment of complication.
CONCLUSIONS:The study demonstrates that costing the treatment pathway using
the bottom-up approach is plausible. In line with existing literature, lifetime costs
of treating AML were found to be high; and it is expected that these findings could
assist decison makers to make informed treatment choices. The costing method
developed in this study could be successfully applied to other diseases with com-
plex treatment pathways.
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OBJECTIVES: For several years, cytotoxic agents have been the backbone of cancer
treatment. There has increasingly, however, been an emergence of new drugs that
are more specific to the target molecule. Some of these novel agents have resulted
in a prolongation of survival and even clinical cures in some cancers. In order to
assess the costs and overall benefits of these new drug therapies, a descriptive
evaluation across seven major tumor types was undertaken. METHODS: A litera-
ture search was conducted from 2000 to 2011 to identify randomized trials of novel
therapies in breast, lung, colorectal, kidney, lymphoma, multiple myeloma and
chronic myelogenous leukemia. Clinical outcomes in terms of progression free
(PFS) and overall survival (OS) benefit were extracted. Economic data in terms of
cost permonth of therapywas obtained from aU.S. cancer clinic. RESULTS:Almost
22 novel therapies were approved across the seven cancers. Four of the 22 (18%)
were used with a curative intent while the remainder were used in the palliative
setting (n18). Ten of these 18 latter agents (56%) also demonstrated an OS benefit.
The median month cost for novel therapies used with a curative intent and those
with a survival benefit in the palliative setting were $5450 and $6450 respectively.
In contrast, the median monthly cost for drugs that did not offer either of these
benefits was $7900. Of the agents identified, imatinib, lenalidomide, rituximab and
trastuzumab provided the greatest magnitude of benefit for both PFS and OS and
would be considered major clinical advances. CONCLUSIONS: Approximately 64%
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